• Subject: RE: Response to: In conclusion: IBM Spin Doctors on AS/400 Marketing
  • From: Neil Palmer <npalmer@xxxxxxxxxxx>
  • Date: Thu, 11 Dec 1997 21:22:16 -0700

Hey Al - does this mean she's one of those ex-IBM Execs who, as of
today, have a lot of time on their hands ?  :-)

Seriously, if Julie offered to assist with this I think it's a good

... Neil Palmer                                     AS/400~~~~~      
... NxTrend Technology - Canada     ____________          ___  ~     
... Thornhill, Ontario,  Canada     |OOOOOOOOOO| ________  o|__||=   
... Phone: (905) 731-9000  x238     |__________|_|______|_|______)   
... Cell.: (416) 565-1682  x238      oo      oo   oo  oo   OOOo=o\   
... Fax:   (905) 731-9202         ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
... mailto:NPalmer@NxTrend.com          http://www.NxTrend.com

        -----Original Message-----
        From:   Al Barsa, Jr. [SMTP:barsa@ibm.net]
        Sent:   Thursday, December 11, 1997 9:26 AM
        To:     midrange-L@midrange.com
        Subject:        Response to: In conclusion: IBM Spin Doctors on
AS/400 Marketing

        This is a quick Thank you note.  Julie Furey (IBM VP in charge
of marketing
        communications) quickly responded to my request to review the
notes, and I
        sent all the notes (120 +-) to her in printed format on Tuesday
night by

        Accolades to Julie, this will be a lot of work if it's done
properly.  I'll
        keep everybody informed.


| This is the Midrange System Mailing List!
| To submit a new message, send your mail to "MIDRANGE-L@midrange.com".
| To unsubscribe from this list send email to MIDRANGE-L-UNSUB@midrange.com.
| Questions should be directed to the list owner/operator: david@midrange.com

This thread ...

Follow On AppleNews
Return to Archive home page | Return to MIDRANGE.COM home page

This mailing list archive is Copyright 1997-2019 by midrange.com and David Gibbs as a compilation work. Use of the archive is restricted to research of a business or technical nature. Any other uses are prohibited. Full details are available on our policy page. If you have questions about this, please contact [javascript protected email address].